Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label Phase III Study of the Efficacy and Safety of Primovist as a Contrast Agent for Enhanced MR Imaging of Focal Liver Lesions in Chinese Patients

NCT00526188 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00526188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00526188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label Phase III Study of the Efficacy and Safety of Primovist as a Contrast Agent for Enhanced MR Imaging of Focal Liver Lesions in Chinese Patients
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2007
Completion date
August 31, 2008
Enrollment
234 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

known or suspected focal liver lesions